Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.

Alexander J EustaceNeil T ConlonMartina S J McDermottBrigid C BrownePatrick O'LearyFrankie A HolmesVirginia EspinaLance A LiottaJoyce O'ShaughnessyClair GallagherLorraine O'DriscollSweta RaniStephen F MaddenNeil A O'BrienCharles GintherDennis SlamonNaomi WalshWilliam M GallagherRadoslaw ZagozdzonWilliam R WatsonNorma O'DonovanJohn Crown

Published in: BMC cancer (2018)

Our findings highlight the possibility of targeting altered apoptotic signalling to overcome acquired lapatinib resistance, and identify potential novel treatment strategies, with potential biomarkers, for HER2-positive breast cancer that is resistant to HER2 targeted therapies.

Keyphrases

positive breast cancer
breast cancer cells
cell death
oxidative stress
endoplasmic reticulum stress
cell cycle arrest
cancer therapy
anti inflammatory
risk assessment
human health
cell proliferation
drug delivery